Insulet | PODD - Current Liabilities


Insulet reported $814.4M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
Align Technology USD 1.91B 4.9M Sep/2026
AtriCure USD 83.97M 2.06M Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Becton, Dickinson and Co. USD 9.54B 139M Sep/2026
Boston Scientific USD 5.98B 446M Sep/2026
Cardinal Health USD 46.33B 2.42B Sep/2026
Cooper Companies USD 1.87B 61.9M Jun/2026
Dexcom USD 2.25B 105.1M Sep/2026
Edwards Lifesciences USD 1.58B 68.8M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Globus Medical USD 507.94M 28.59M Sep/2026
ICU Medical USD 514.63M 16.27M Sep/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 814.4M 70.2M Sep/2026
Integra LifeSciences USD 329M 1.88M Sep/2026
J&J USD 55.46B 562M Sep/2026
Medtronic USD 11.8B 141M Jun/2026
Merit Medical Systems USD 265.08M 150K Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Solventum Corp USD 3.58B 88M Sep/2026
Stryker USD 6.5B 184M Sep/2026
Tandem Diabetes Care USD 256.08M 3.07M Sep/2026
Teleflex USD 917.1M 196.72M Sep/2026
West Pharmaceutical Services USD 644.3M 3.8M Sep/2026
Zimmer Biomet Holdings USD 3.5B 488.9M Sep/2026